- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Tesh Khullar Outlines Efforts Needed to Make Sure Providers Are Comfortable Prescribing Biosimilars
Tesh Khullar, senior vice president & advisor, Flatiron Health, explains what efforts are needed to make sure providers are comfortable prescribing biosimilars.
Tesh Khullar, senior vice president & advisor, Flatiron Health, explains what efforts are needed to make sure providers are comfortable prescribing biosimilars.
Transcript
What efforts are needed to providers are comfortable with prescribing biosimilars?
I think education around what biosimilars actually are and so, the physicians I talk to give me a great analogy that they’re using biosimilars right now because of the way monoclonal antibodies are made, one batch of Rituxan is different right now than a batch of Rituxan made 2 years ago. So essentially, you’re using a biosimilar right now, and as long as there’s a cost incentive to use cheaper therapies, I think the consumers are going to look at it just like they look at generics. That’s what I believe is going to happen.
